NDAORALTABLETPriority Review
Approved
Mar 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
SYMFI (efavirenz, lamivudine and tenofovir disoproxil fumarate) by Viatris is non-nucleoside reverse transcriptase inhibitors [moa]. First approved in 2018.
Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SYMFI is a fixed-dose combination tablet containing efavirenz, lamivudine, and tenofovir disoproxil fumarate for the treatment of HIV-1 infection. It works by inhibiting reverse transcriptase, a key enzyme required for HIV replication. This oral combination therapy simplifies dosing by consolidating three antiretroviral agents into a single tablet.
$0.001BPart D
PeakProduct is in peak commercial phase with established market penetration; teams likely focused on market maintenance and existing account management rather than rapid expansion.
Mechanism of Action
Non-Nucleoside Reverse Transcriptase Inhibitors
Pharmacologic Class:
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SYMFI positions professionals in the stable but competitive HIV therapeutics space, which offers strong healthcare system relationships and established prescriber networks. This is a maintenance-focused role rather than a launch role, emphasizing relationship management and market defense over new market creation.
Brand Manager
Worked on SYMFI at Viatris? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.